Sugen
About Sugen
Sugen is a biotechnology company that specializes in target-driven drug discovery and development for novel development-stage cancer therapies. It develops new therapeutic approaches to various diseases through its development of small molecule inhibitors that regulate particular signaling pathways. Sugen owns three anti-cancer drugs in clinical development, including novel cytostatic agents and angiogenesis inhibitors. In addition to its current focus in oncology, Sugen is applying its technology platform to identify and validate novel targets for a range of potential clinical applications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Funding stage: M&A
- Last round: Pre-Seed (Jan 1991)
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/sugen-2996057 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.